Tag: B-cell malignancy
Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma
1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...
KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia
1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...
#VisualAbstract: Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...